Skip to main
We’re doing some system maintenance
  1. /
  2. Stocks
  3. /
  4. ADC Therapeutics
ADCT

Buy ADC Therapeutics (ADCT) Stock

ADCT
See ADCT stock price and Buy/Sell ADC Therapeutics with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing
ADCT

ADC Therapeutics (ADCT)

About ADC Therapeutics (ADCT)

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and...Read more
Market Cap
$402.49M
1 Year High
$32
Volume
84.16k
1 Year Low
$4.58
Price to Earnings Ratio
Open
$5.07
Dividend Rate
High
$5.14
Dividend Yield
Low
$4.87

Community

People who own or watch ADCT stock

ADC Therapeutics Price Targets

What analysts think ADCT stock price will be.
$5.11
$17.67
245.8% Upside
$4$34

ADC Therapeutics Stock Rating

What analysts recommend for ADCT stock, on a scale from 1(buy) to 5(sell).
Buy1.9 / 5
BuyHoldSell

ADC Therapeutics Stock Earnings

The value each ADCT share was expected to gain vs. the value that each ADCT share actually gained.
Expected
Actual

ADC Therapeutics Stock News

Frequently Asked Questions (FAQ)

As of Oct 04, 2022, the market cap for ADCT stock is $402.49M

The 52-week high for ADCT stock is $32. The current ADCT stock price $5.11 is 84.03% below its 52-week high

The 52-week low for ADCT stock is $4.58. The current ADCT stock price $5.11 has increased 10.37% from its 52-week low

No, the ADCT stock does not pay dividends to its shareholders

The target price for ADCT stock is $17.67 based on the average of what a group of analyst think ADCT stock could be worth at a future date. This is not a prediction by Public.com

Buy ADC Therapeutics (ADCT) Stock

ADCT
See ADCT stock price and Buy/Sell ADC Therapeutics with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Community

People who own or watch ADCT stock
  • AntoniaCruzLeon avatar
  • jp904 avatar
  • Nicky871 avatar
  • melenaleona avatar
  • rayray21 avatar
Products
Contact Us
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

Brokerage services for US-listed, registered securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings, Inc. (“Public Holdings”). This is not an offer, solicitation of an offer, or advice to buy or sell securities or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Our clearing firm, Apex Clearing Corporation, has purchased an additional insurance policy. The coverage limits provide protection for securities and cash up to an aggregate of $150 million, subject to maximum limits of $37.5 million for any one customer’s securities and $900,000 for any one customer’s cash. Similar to SIPC protection, this additional insurance does not protect against a loss in the market value of securities.

Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are over-the-counter equity securities that have been issued pursuant to Regulation A of the Securities Act of 1933 (as amended) (“Regulation A”). Dalmore and Open to the Public Investing are not affiliated entities. This content is not investment advice. These investments are speculative, involve substantial risks (including illiquidity and loss of principal), and are not FDIC or SIPC insured. The issuers of these securities may be an affiliate of Public, and Public (or an affiliate) may earn fees when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, see these disclosures. An affiliate of Public may be “testing the waters” and considering making an offering of securities under Tier 2 of Regulation A. No money or other consideration is being solicited and, if sent in response, will not be accepted. No offer to buy securities can be accepted, and no part of the purchase price can be received, until an offering statement filed with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification by the SEC or as stated in the offering materials relating to an investment opportunity, as applicable. An indication of interest to purchase securities involves no obligation or commitment of any kind.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures, Apex Crypto.

Dalmore and Apex Crypto, LLC are not affiliated with any of the Public Holdings subsidiaries.

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S.-listed, registered securities electronically. Keep in mind that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more. All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.